Publication number: 20210254062
Abstract: Among other things, the present disclosure provides designed DMD oligonucleotides, compositions, and methods of use GC thereof. In some embodiments, the present disclosure provides technologies useful for repairing mutant DMD transcripts by skipping exon 51 or exon 53, so that the transcript can be translated into an internally truncated but at least partially functional Dystrophin protein variant. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) DMD transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as muscular dystrophy, including but not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.
Type:
Application
Filed:
May 10, 2019
Publication date:
August 19, 2021
Applicant:
WAVE LIFE SCIENCES LTD.
Inventors:
Jason Jingxin Zhang, Chandra Vargeese, Naoki Iwamoto, Chikdu Shakti Shivalila, Nayantara Kothari, Ann Fiegen Durbin, Selvi Ramasamy, Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Gopal Reddy Bommineni, Subramanian Marappan, Sethumadhavan Divakaramenon, David Charles Donnell Butler, Genliang Lu, Hailin Yang, Mamoru Shimizu, Prashant Monian